At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 12, 2026 at 16:10 ET
Relmada reported Q3 2026 net loss of $13.9M ($0.12/share), wider than the $10.1M loss in Q3 2025, driven by increased R&D spending on NDV-01 and sepranolone trial preparation. The company highlighted positive 18-month Phase 2 durability data for NDV-01 in NMIBC and confirmed it remains on track to submit the NDV-01 IND by year-end 2026. Cash of $202.1M is expected to fund operations through 2029.
- Q3 2026 net loss of $13.9M ($0.12/share) vs $10.1M ($0.30/share) in Q3 2025
- R&D expense increased to $9.2M from $4.0M year-over-year due to NDV-01 and sepranolone preparation costs
- Cash, cash equivalents and short-term investments of $202.1M as of September 30, 2026
- NDV-01 CMC program on track for IND submission by year-end 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access